DIRS.INFO The most relevant business & tech news

☆ These stocks will be the winners and losers of rising U.S.-China trade tensions, Wall Street says
▼ + stars: | 2024-07-19 | by ( Weizhen Tan | ) www.cnbc.com time to read: +5 min

For Europe, the prime concern is tariffs," wrote Goldman analysts. "If the entire impact came in 2025 this would be enough to eliminate any growth that year (our current top-down forecast is 4%)," Goldman wrote. Within sectors, beneficiaries of rising trade risks tend to be defensive stocks such as utilities, health care as well as Europe's GRANOLAS stocks, according to the bank. But he says a "meaningful selloff" in mega tech will see other names "pushed down as collateral damage." And if the AI narrative plays out as expected, a material sell-off in Mega Tech will present a buying opportunity in those names as well," he wrote.

Persons: Biden, Donald Trump, Trump, Europe's, Goldman Sachs, Goldman, Louis Navellier, — CNBC's Michael Bloom Organizations: Bloomberg, Taiwan, Trump, U.S, JPMorgan, China Gas, Power, Huaneng, Republicans, National Security, Hire, GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP, Sanofi, Liquide, Tobacco, Dassault Systemes, Intercontinental Hotels, Nvidia, Navellier, Associates, Mega Tech Locations: China, Taiwan, U.S, Hong Kong, Europe, United States, Germany, France, Stellantis

☆ Huma, a London-based healthcare startup, just raised $80 million to offer new AI services using this 11-slide pitch deck
▼ + stars: | 2024-07-16 | by ( Callum Burroughs | ) www.businessinsider.com time to read: +2 min

Read previewHuma, an AI digital healthcare company, has raised $80 million in Series D funding. "AI is core to how we build scalable digital health solutions," Huma CEO Dan Vahdat, told Business Insider. "It is a challenging environment for digital health companies in general, particularly with the public markets being down," Vahdat added. The company's $80 million Series D funding round was raised by new and existing investors such as AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, and Leaps by Bayer. Check out Huma's 11-slide Series D pitch deck below:

Persons: —, Dan Vahdat, Huma, Sifted, Vahdat Organizations: Service, Business, Bayer, AstraZeneca, Hat Technology, HAT, Hitachi Ventures Locations: Swedish

☆ The CEO of Cerebras, which could go public soon, takes on Nvidia in a David and Goliath battle for AI chip supremacy
▼ + stars: | 2024-07-15 | by ( Emma Cosgrove | ) www.businessinsider.com time to read: +5 min

Few would envy the task of competing against market leader Nvidia, which has between 70% and 90% market share, according to Mizuho Securities. Still, Nvidia gets most of the hype — and the revenue. Though the company will not confirm it, The Information reported last month that Cerebras has confidentially filed for an IPO. Still, Feldman expects that even consumer-directed AI models will grow larger, and larger models need faster chips. Competing with that mindshare is an uphill battle as Nvidia faces more competition and goes on defense.

Persons: —, Andrew Feldman, I'm, Feldman, Cerebras, David, He's, Cerebras's, Ramsey Cardy Cerebras, Susan Organizations: Service, Palo, Nvidia, Mizuho Securities, Business, Big Tech, Intel, Google, AMD, GSK, AstraZeneca, IBM, Eclipse Ventures Locations: California, Palo Alto , California, It's

☆ How to invest $100,000 when stocks are at all-time highs? Here's what two wealth managers say
▼ + stars: | 2024-06-17 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

As stock markets press against all-time highs driven by the potential of artificial intelligence, the question of how to invest $100,000 has become more urgent than ever. "But perhaps relative to the global equity universe, we would probably have a bit more outside of the United States." Echoing that view, Matthews says he sees opportunities in equity markets, particularly in small- and mid-cap stocks in the United Kingdom and Europe. "We have been adding to this area in the U.K. through Chelverton United Kingdom Equity Growth Fund ." Looking ahead, Flax acknowledges the potential impact of political risks like upcoming elections in the United Kingdom and the United States.

Persons: Richard Flax, Moneyfarm, Robert Matthews, WH, they've, Matthews, Flax, — Organizations: CNBC Pro, WH Ireland, CNBC, Chelverton United Kingdom Equity Growth, Health, AstraZeneca, HICL Infrastructure PLC Locations: United States, United Kingdom, Europe, London, U.S

☆ Move over 'Magnificent 7,' the 'Fantastic 5' may offer higher earnings and return potential
▼ + stars: | 2024-06-06 | by ( Pia Singh | ) www.cnbc.com time to read: +6 min

Looking for a less risky way to find growth stocks amid all the artificial intelligence hype? Looking ahead, Thornburg expects the Fantastic Five's outperformance to continue, with the forward price-to-earnings ratio of the European group falling below the seven U.S. stocks starting in 2026 and running through 2028. The money manager also projected that the European group will increase earnings 18% a year over the next three years versus 14% for the "Mag 7." ASML, the biggest producer of the equipment used to manufacture semiconductors, makes "leading-edge" lithography equipment needed to produce AI chips, Anderson said. He manages the Thornburg International Growth Fund , a concentrated portfolio of high-quality companies based outside the U.S., which has gained 8.8% year-to-date.

Persons: Nicholas Anderson, Anderson, Thornburg, It's, it's, FactSet, ASML Organizations: Thornburg Investment Management, Novo Nordisk, ASML, LVMH, AstraZeneca, SAP, Nvidia, Big Tech, Microsoft, Apple, GLP, Nordisk, Taiwan Semiconductor, Bloomberg, Growth Fund Locations: U.S, Novo, Europe, Belgium

☆ AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
▼ + stars: | 2024-06-04 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca CEO Pascal Soriot goes one-on-one with Jim CramerAstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.

Persons: Pascal Soriot, Jim Cramer

☆ Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
▼ + stars: | 2024-06-04 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

AstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the drugmaker believes it can almost double revenue by 2030. The pharmaceutical giant also plans to release 20 new drugs by 2030, half of which will treat cancer, Soriot said. The company recently released promising results about several of its cancer drugs at the American Society of Clinical Oncology's annual meeting, including ones for lung and breast cancers. Soriot said researchers are quickly developing new and promising cancer treatments. He said new cell therapies have the potential to cure patients, and he also pointed to antibody-drug conjugates — which, unlike chemotherapy, aim to target cancer cells while sparing healthy ones.

Persons: Pascal Soriot, CNBC's Jim Cramer, we're, Soriot Organizations: AstraZeneca, American Society, Clinical, CNBC

☆ We're in a difficult business but have the right level of confidence, says AstraZeneca CEO
▼ + stars: | 2024-06-04 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe're in a difficult business but have the right level of confidence, says AstraZeneca CEOAstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.

Persons: Pascal Soriot, Jim Cramer

☆ Cramer’s Stop Trading: AstraZeneca
▼ + stars: | 2024-06-03 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer’s Stop Trading: AstraZenecaCNBC’s Jim Cramer explains why he is keeping an eye on shares of AstraZeneca.

Persons: Jim Cramer Organizations: AstraZeneca

☆ Cramer's Lighting Round: 'You've got a winner' with Astra Zeneca
▼ + stars: | 2024-05-31 | by ( Julie Coleman | ) www.cnbc.com time to read: 1 min

Viking Therapeutics : "I say you need to be in Eli Lilly. Step your game up, partner." AstraZeneca : "This is an amazing team that they've got at AstraZeneca now, and they've got fantastic formulations in oncology, but also heart. And they have a GLP-1 kind of thing going on, but it's a little far removed...You've got a winner with AstraZeneca."

Persons: Eli Lilly, they've, You've Organizations: Viking Therapeutics, AstraZeneca

☆ Lightning Round: You don't want to be in Hawaiian Electric, says Jim Cramer
▼ + stars: | 2024-05-31 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: You don't want to be in Hawaiian Electric, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Viking Therapeutics, H.B. Fuller, AstraZeneca, and Hawaiian Electric.

Persons: Jim Cramer, Fuller Organizations: Viking Therapeutics, AstraZeneca, Electric

☆ Here are Thursday's biggest analyst calls: Apple, Nvidia, Salesforce, Amazon, Okta, Eli Lilly, Cava, PayPal & more
▼ + stars: | 2024-05-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Goldman Sachs initiates Abbott Labs as buy Goldman said Abbott is well positioned for growth. UBS reiterates Apple as neutral UBS said its checks show iPhone pressure remains in China and the U.S. for Apple. Goldman Sachs reiterates Eli Lilly as neutral Goldman raised its price target on Eli Lilly to $785 per share from $740. Goldman Sachs reiterates Salesforce as buy Goldman said it's sticking with the stock following earnings on Wednesday. Goldman Sachs initiates AstraZeneca, Novartis and Novo Nordisk as buy Goldman initiated several biotech company's on Thursday and says it sees "innovation momentum a key focus."

Persons: Baird, OKTA, Goldman Sachs, Abbott, Goldman, Piper Sandler downgrades Cava, Piper, Eli Lilly, Wells Fargo, Wells, Mizuho, Wedbush, Daiwa, Stifel, it's, Salesforce, CRM's, Redburn, Guggenheim, Generac Organizations: UBS, Apple, Mizuho, PayPal, Bank of America, Gross, Amicus, USM, First, Deutsche Bank, Deutsche, JPMorgan, Nvidia, Technology, Northland, AstraZeneca, Novartis, Novo Nordisk, of America, TAM, Guggenheim Locations: China, Corning, Northland, 4Q24

☆ A corner of the cancer therapy market is heating up—Here are the names investors need to know
▼ + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +8 min

A $25 billion market Meanwhile, RBC Capital Markets sees a $25 billion market opportunity for the space. A name Jones likes is Perspective Therapeutics , which he rates outperform. CATX 1Y mountain Perspective Therapeutics year to date Cantor Fitzgerald is also bullish on the name. So it's really an ideal profile," said Piper Sandler analyst Edward Tenthoff, who doesn't cover Perspective Therapeutics. Then there is Lantheus Holdings , which calls itself a radiopharmaceutical-focused company and has a $5.6 billion market cap.

Persons: There's, Eli Lilly, Myers, Jefferies, Andrew Tsai, radiopharma, Oppenheimer, Jeff Jones, FactSet, William Blair, Read, — it's, Andy Hsieh, Gregory Renza, Jones, Cantor Fitzgerald, Louise Chen, it's, Piper Sandler, Edward Tenthoff, Dan Lyons, Janus Henderson, Lantheus, Roanna Ruiz Organizations: Novartis, pharma, Mariana Oncology, Myers Squibb, AstraZeneca, Fusion Pharmaceuticals, RBC Capital Markets, TRT, Therapeutics, Alpha, Janus, Janus Henderson Investors, Lantheus Holdings, Lantheus, Leerink, ~$ Locations: Biopharma, Bristol, Mariana, radiopharma, New Jersey

☆ This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
▼ + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +7 min

RBC Capital Markets sees a $25 billion market opportunity for the space. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet. Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance

Persons: It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers Organizations: pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto Locations: Mariana, Bristol

☆ AstraZeneca targets $80 billion in total revenue by 2030 in 'post-Covid era'
▼ + stars: | 2024-05-21 | by ( Sophie Kiderlin | In | ) www.cnbc.com time to read: +2 min

Costfoto | Future Publishing | Getty ImagesLONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca will focus on its oncology, biopharmaceuticals and rare diseases businesses and expects to release an additional 20 medicines in the next six years. "Many of them have the potential to be $5 billion drugs," Sarin noted. A company statement detailed that this revenue figure could be hit annually for many of the new medicines in peak years. "For the entire market to get replaced it will take time, but we think we have the technology today to start replacing them," Sarin told CNBC.

Persons: CNBC's Arabile Gumede Organizations: Astrazeneca, Artificial Intelligence, — Pharmaceutical, AstraZeneca, CNBC, U.S . FDA, Pharmaceuticals, Investments Locations: Shanghai, China, Europe, London, Singapore

☆ Stocks making the biggest moves midday: Peloton, Lam Research, Lowe's, AstraZeneca and more
▼ + stars: | 2024-05-21 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Lowe's — The home improvement stock fell 2.9% despite the company posting a first-quarter earnings and revenue beat. By comparison, analysts surveyed by FactSet had penciled in $1.45 in earnings per share on $1.21 billion in revenue. XPeng — U.S-listed shares jumped nearly 5% after the Chinese EV company topped first-quarter estimates for revenue and said it anticipates a rise in quarterly deliveries. AutoZone reported $4.24 billion in revenue for the quarter, below the $4.29 billion expected by analysts, according to FactSet. Sprout Social — Shares dropped 4% after Sprout Social responded to a Reuters report, citing sources familiar, that said its founders are in talks to take the social media strategy company private.

Persons: Lam, Macy's, Tony Spring, Marvin Ellison, BlackLine, FactSet, Keysight, AutoZone, Li Auto, Li, Yun Li, Jesse Pound, Sarah Min, Alex Harring, Lisa Han, Samantha Subin Organizations: AstraZeneca — U.S, Traffic Safety Administration, Dell Technologies, Citi, Baird, Palo Alto Networks, Keysight, EV, Reuters, Li Auto Locations: billings, —

☆ CNBC Changemaker & AstraZeneca CFO celebrates AANHPI Heritage Month
▼ + stars: | 2024-05-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCNBC Changemaker & AstraZeneca CFO celebrates AANHPI Heritage MonthAstraZeneca Group CFO Aradhana Sarin says she's proud of her upbringing and the wide cultural understanding that came with it.

Organizations: CNBC, AstraZeneca, Heritage

☆ Pfizer and AstraZeneca announce new investments of nearly $1 billion in France
▼ + stars: | 2024-05-12 | by ( ) www.cnbc.com time to read: +1 min

Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit. Pfizer said it would invest 500 million euros ($538.5 million) in France to build up its research and development work in the country, while AstraZeneca announced an investment of $388 million for its site at Dunkirk. France announced earlier on Sunday 100 new jobs in Paris at Wall Street bank Morgan Stanley, and investments from other firms such as German aviation company Lilium . Macron wants to burnish Paris' role as a top European business capital, although it has traditionally lagged New York and London on a global scale. The survey ranked Paris in 14th position.

Persons: Emmanuel Macron, Morgan Stanley, Macron, Paris Organizations: Pfizer, AstraZeneca, Wall, New York, London Locations: France, Dunkirk, Paris, New York, London, New

☆ AstraZeneca Is Withdrawing Its Covid Vaccine Worldwide, Citing Low Demand
▼ + stars: | 2024-05-08 | by ( Rebecca Robbins | More About Rebecca Robbins | ) www.nytimes.com time to read: +1 min

AstraZeneca has started to pull its Covid-19 vaccine from global markets because of low demand, the pharmaceutical giant said. The move was not related to any concerns about the shot’s side effects, the company said. Since the vaccine was approved in Britain in December 2020, over three billion doses have been supplied globally. The company said that it had decided to voluntarily withdraw all licenses to market its Covid vaccine. In March, AstraZeneca requested that the vaccine be withdrawn from most European countries.

Organizations: AstraZeneca, Oxford University, European Commission Locations: Britain

☆ AstraZeneca to withdraw Covid vaccine worldwide, citing a drop in demand
▼ + stars: | 2024-05-08 | by ( Sophie Kiderlin | In | ) www.cnbc.com time to read: +2 min

In this photo illustration a covid-19 vaccine is seen with the AstraZeneca logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined. Demand for the Vaxzevria vaccine has tailed off as new vaccines tailored to specific Covid variants have emerged, AstraZeneca said in a statement. "As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines. Next to Covid vaccines, AstraZeneca has been working on a range of other treatments for illnesses including cancer.

Persons: Nikos Pekiaridis Organizations: AstraZeneca, Getty Images, Pharmaceutical, University of Oxford, Covid, World Health Organization, European Union, Fusion Pharmaceuticals Inc Locations: U.K

☆ AstraZeneca withdraws Covid-19 vaccine citing low demand
▼ + stars: | 2024-05-08 | by ( Hanna Ziady | ) edition.cnn.com time to read: +1 min

London CNN —AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand. But the vaccine has not generated revenue for AstraZeneca since April 2023, the company said. “As multiple, variant Covid-19 vaccines have … been developed, there is a surplus of available updated vaccines. “AstraZeneca has therefore taken the decision to initiate withdrawal of the marketing authorizations for Vaxzevria within Europe,” it added. AstraZeneca said it would work with regulators in other countries to “align on a clear path forward,” including withdrawing marketing authorizations for the vaccine where no future commercial demand is expected.

Persons: University of Oxford —, “, Vaxzevria, ” AstraZeneca Organizations: London CNN, AstraZeneca, University of Oxford, CNN, “ AstraZeneca, European Medicines Agency, Union Locations: United Kingdom, Vaxzevria, Europe

☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
▼ + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com time to read: +10 min

Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield

☆ FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster drugs Ozempic, Saxenda and Victoza. The FTC issued letters to 10 companies, warning them that certain drug patents were improperly listed. Many of the drug patents are for Type 2 diabetes, along with asthma and inhalers for chronic obstructive pulmonary disease, or COPD. Generic drugmakers can only launch cheaper versions of a branded drug if the patents have expired or are successfully challenged in court. The FTC first challenged dozens of branded drug patents last fall, leading three drugmakers to comply and delist their patents with the FDA.

Persons: Novo, Boehringer, Lina Khan, Biden, drugmakers, Joe Biden's Organizations: Federal Trade Commission, FTC, Novo Nordisk, AstraZeneca, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Food and Drug Administration, FDA Locations: U.S

☆ Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
▼ + stars: | 2024-04-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A federal judge in New Jersey on Monday rejected Johnson & Johnson 's and Bristol Myers Squibb 's legal challenges to the Biden administration's Medicare drug-price negotiations, ruling that the program is constitutional. J&J and Bristol Myers Squibb did not immediately respond to requests for comment on the ruling. J&J, Bristol Myers Squibb, Novo Nordisk and Novartis presented their oral arguments before Quraishi during the same hearing in March. That same month, a federal judge in Delaware rejected AstraZeneca's separate lawsuit challenging the negotiations. In Texas, a third federal judge tossed a separate lawsuit in February.

Persons: Johnson, Bristol Myers, Joe Biden's, Zahid Quraishi, Quraishi, Bristol Myers Squibb's, AstraZeneca's Organizations: Bristol, Bristol Myers Squibb, Biden, White, Supreme, Final, of New, Novo Nordisk, Novartis, Chamber of Commerce Locations: New Jersey, U.S, of New Jersey, Delaware, Texas, Ohio

☆ AstraZeneca tops first-quarter revenue and profit expectations
▼ + stars: | 2024-04-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca tops first-quarter revenue and profit expectationsAstraZeneca CEO Pascal Soriot outlines how the pharma giant's first-quarter results were boosted by demand for its rare blood disorder and oncology drugs.

Persons: Pascal Soriot Organizations: AstraZeneca, pharma

Search resuls for: "AstraZeneca"

25 mentions found